Ali Behbahani - 01 Jul 2026 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Reporting relationship: Director
Issuer ticker: GLUE
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2026, 17:57:07 UTC
Prior SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Zachary Bambach, attorney-in-fact

Key filing fact

Ali Behbahani filed Form 4 for Monte Rosa Therapeutics, Inc. (GLUE) on 06 Jul 2026.

Key facts

This page summarizes Ali Behbahani's Form 4 filing for Monte Rosa Therapeutics, Inc. (GLUE).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Jul 2026, 17:57.

Change

Previous filing in this sequence was filed on 29 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001613867 Primary reporting owner

Behbahani Ali

Relationship: Director
Address: 2855 SAND HILL ROAD, MENLO PARK
Signature: /s/ Zachary Bambach, attorney-in-fact
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GLUE transaction

Common Stock

Other

Transaction value
Shares: -1,000,000
Change %: -13%
Price: $0.000000^*
Shares after: 6,692,298
Date: 01 Jul 2026
Ownership: See Note 2
Footnotes: F1, F2

GLUE transaction

Common Stock

Other

Transaction value
Shares: +15,000
Change %
Price: $0.000000^*
Shares after: 15,000
Date: 01 Jul 2026
Ownership: See Note 4
Footnotes: F3, F4

GLUE transaction

Common Stock

Other

Transaction value
Shares: -15,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Jul 2026
Ownership: See Note 4
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

New Enterprise Associates 17, L.P. ("NEA 17") made a pro rata distribution of 1,000,000 shares of Common Stock of the Issuer to its general partner and limited partners for no consideration on July 1, 2026.

Footnote F2

The Reporting Person is a manager of NEA 17 GP, LLC ("NEA 17 GP"), which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of NEA 17, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Footnote F3

NEA Partners 17 received 15,000 shares of Common Stock of the Issuer in the distribution made by NEA 17 on July 1, 2026.

Footnote F4

The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest.

Footnote F5

NEA Partners 17 made a distribution of 15,000 shares of Common Stock of the Issuer for no consideration on July 1, 2026.